274 related articles for article (PubMed ID: 33150251)
1. Roles of the
Takahashi M; Kawai K; Asai N
JMA J; 2020 Jul; 3(3):175-181. PubMed ID: 33150251
[No Abstract] [Full Text] [Related]
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
3. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
Asai N; Jijiwa M; Enomoto A; Kawai K; Maeda K; Ichiahara M; Murakumo Y; Takahashi M
Pathol Int; 2006 Apr; 56(4):164-72. PubMed ID: 16634961
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene.
Decker RA; Peacock ML
J Pediatr Surg; 1998 Feb; 33(2):207-14. PubMed ID: 9498388
[TBL] [Abstract][Full Text] [Related]
5. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
6. The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.
Kusafuka T; Puri P
Pediatr Surg Int; 1997; 12(1):11-8. PubMed ID: 9035202
[TBL] [Abstract][Full Text] [Related]
7. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases.
Runeberg-Roos P; Saarma M
Ann Med; 2007; 39(8):572-80. PubMed ID: 17934909
[TBL] [Abstract][Full Text] [Related]
8. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
[TBL] [Abstract][Full Text] [Related]
9. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
10. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
11. An extended family with familial medullary thyroid carcinoma and Hirschsprung's disease.
Igarashi T; Okamura R; Jikuzono T; Uchino S; Sugitani I; Shimizu K
J Nippon Med Sch; 2014; 81(2):64-9. PubMed ID: 24805091
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic activation of the ret protooncogene in thyroid cancer.
Takahashi M
Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
Recent Results Cancer Res; 1998; 154():229-36. PubMed ID: 10027003
[TBL] [Abstract][Full Text] [Related]
15. [Neural crest and multiple endocrinopathies].
Pasini A; Michiels FM; Chappuis-Flament S; Geneste O; Rossel M; Fournier L; Feunteun J; Lenoir G; Schuffenecker I; Billaud M
C R Seances Soc Biol Fil; 1996; 190(5-6):557-67. PubMed ID: 9074721
[TBL] [Abstract][Full Text] [Related]
16. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.
Romeo G; Ronchetto P; Luo Y; Barone V; Seri M; Ceccherini I; Pasini B; Bocciardi R; Lerone M; Kääriäinen H
Nature; 1994 Jan; 367(6461):377-8. PubMed ID: 8114938
[TBL] [Abstract][Full Text] [Related]
17. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.
Marshall GM; Peaston AE; Hocker JE; Smith SA; Hansford LM; Tobias V; Norris MD; Haber M; Smith DP; Lorenzo MJ; Ponder BA; Hancock JF
Cancer Res; 1997 Dec; 57(23):5399-405. PubMed ID: 9393766
[TBL] [Abstract][Full Text] [Related]
18. Putting the bits and pieces of the RET proto-oncogene puzzle together.
Gagel RF
Bone; 1995 Aug; 17(2 Suppl):13S-16S. PubMed ID: 8579892
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
[TBL] [Abstract][Full Text] [Related]
20. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
Gujral TS; Mulligan LM
Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]